|
Volumn 165, Issue 9, 2005, Pages 1066-1067
|
Are cyclooxygenase-2 inhibitors being taken only by those who need them?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CELECOXIB;
CYCLOOXYGENASE 2 INHIBITOR;
NONSTEROID ANTIINFLAMMATORY AGENT;
ROFECOXIB;
VALDECOXIB;
ARTICLE;
CLINICAL TRIAL;
DRUG SAFETY;
DRUG WITHDRAWAL;
DUODENITIS;
DUODENUM ULCER;
ESOPHAGITIS;
GASTRITIS;
GASTROINTESTINAL HEMORRHAGE;
HEART INFARCTION;
HIGH RISK PATIENT;
HUMAN;
LIVER CIRRHOSIS;
PRESCRIPTION;
PRIORITY JOURNAL;
STOMACH ULCER;
TREATMENT OUTCOME;
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;
CYCLOOXYGENASE INHIBITORS;
DRUG UTILIZATION;
GASTROINTESTINAL DISEASES;
HEALTH CARE SURVEYS;
HUMANS;
PATIENT SELECTION;
PRESCRIPTIONS, DRUG;
RISK ASSESSMENT;
|
EID: 18344390561
PISSN: 00039926
EISSN: None
Source Type: Journal
DOI: 10.1001/archinte.165.9.1066 Document Type: Article |
Times cited : (6)
|
References (6)
|